{"denoms":[{"counts":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"49"}],"units":"Participants"}],"groups":[{"description":"Patients undergo observation until disease progression.","id":"BG000","title":"Arm A (Observation)"},{"description":"Patients receive pemetrexed 500 mg/m2 IV over 10 minutes (or per institutional guidelines) every three weeks. Patients will continue treatment until disease progression or excess toxicity.","id":"BG001","title":"Arm B (Pemetrexed)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.2","value":"68.1"},{"groupId":"BG001","spread":"9.0","value":"71.0"},{"groupId":"BG002","spread":"9.6","value":"69.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"13"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"36"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}]}],"title":"Unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"44"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Black/African American"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"49"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"15"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"34"}]}],"title":"1"}],"description":"Eastern Cooperative Oncology Group PS Scale: 0)Fully active, able to carry on all pre-disease performance without restriction; 1)Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2)Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours; 3)Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours; 4)Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}]}